Applied Genetic Technologies Corporation

NasdaqGM:AGTC Stock Report

Market Cap: US$12.6m

This company has been acquired

The company may no longer be operating, as it has been acquired. Find out why through their latest events.

Applied Genetic Technologies Management

Management criteria checks 1/4

Key information

Sue Washer

Chief executive officer

US$1.5m

Total compensation

CEO salary percentage37.4%
CEO tenure20.7yrs
CEO ownership0.2%
Management average tenure1.4yrs
Board average tenure11.3yrs

Recent management updates

Recent updates

AGTC receives positive feedback from FDA for manufacturing facility

Jul 26

Applied Genetic Technologies proposes stock offering to fund clinical trials

Jul 12

Applied Genetic Tech: A Speculative Biotech With Potential To Turn Corner In 2022

Jan 12

An Assessment Of Applied Genetic Technologies Corporation

Dec 14

Applied Genetic Technologies: Weak Early Clinical Ocular Results Highlight Increased Risk

Jul 15

Is Applied Genetic Technologies (NASDAQ:AGTC) A Risky Investment?

May 21
Is Applied Genetic Technologies (NASDAQ:AGTC) A Risky Investment?

Applied Genetic trades lower after announcing the departure of chief scientific officer

Apr 26

What Is The Ownership Structure Like For Applied Genetic Technologies Corporation (NASDAQ:AGTC)?

Feb 05
What Is The Ownership Structure Like For Applied Genetic Technologies Corporation (NASDAQ:AGTC)?

Is Applied Genetic Technologies (NASDAQ:AGTC) Using Debt In A Risky Way?

Jan 06
Is Applied Genetic Technologies (NASDAQ:AGTC) Using Debt In A Risky Way?

What Type Of Returns Would Applied Genetic Technologies'(NASDAQ:AGTC) Shareholders Have Earned If They Purchased Their SharesFive Years Ago?

Dec 11
What Type Of Returns Would Applied Genetic Technologies'(NASDAQ:AGTC) Shareholders Have Earned If They Purchased Their SharesFive Years Ago?

Interim data on gene therapy for vision loss disorder fails to lift Applied Genetic

Nov 11

CEO Compensation Analysis

How has Sue Washer's remuneration changed compared to Applied Genetic Technologies's earnings?
DateTotal CompensationSalaryCompany Earnings
Sep 30 2022n/an/a

-US$70m

Jun 30 2022US$1mUS$551k

-US$69m

Mar 31 2022n/an/a

-US$63m

Dec 31 2021n/an/a

-US$63m

Sep 30 2021n/an/a

-US$60m

Jun 30 2021US$1mUS$530k

-US$58m

Mar 31 2021n/an/a

-US$60m

Dec 31 2020n/an/a

-US$57m

Sep 30 2020n/an/a

-US$50m

Jun 30 2020US$988kUS$530k

-US$46m

Mar 31 2020n/an/a

-US$42m

Dec 31 2019n/an/a

-US$19m

Sep 30 2019n/an/a

-US$15m

Jun 30 2019US$1mUS$514k

-US$2m

Mar 31 2019n/an/a

US$2m

Dec 31 2018n/an/a

-US$18m

Sep 30 2018n/an/a

-US$19m

Jun 30 2018US$1mUS$502k

-US$21m

Mar 31 2018n/an/a

-US$18m

Dec 31 2017n/an/a

-US$11m

Sep 30 2017n/an/a

-US$4m

Jun 30 2017US$1mUS$487k

US$407k

Mar 31 2017n/an/a

US$6m

Dec 31 2016n/an/a

US$10m

Sep 30 2016n/an/a

US$11m

Jun 30 2016US$2mUS$464k

-US$1m

Compensation vs Market: Sue's total compensation ($USD1.47M) is above average for companies of similar size in the US market ($USD749.50K).

Compensation vs Earnings: Sue's compensation has increased whilst the company is unprofitable.

CEO

Sue Washer (61 yo)

20.7yrs

Tenure

US$1,473,567

Compensation

Ms. Susan B. Washer, also known as Sue, has been the President and Chief Executive Officer of Applied Genetic Technologies Corporation since March 2002. Ms. Washer is an experienced entrepreneur with a str...

Leadership Team

NamePositionTenureCompensationOwnership
Susan Washer
President20.7yrsUS$1.47m0.21%
$ 26.7k
Jonathan Lieber
Chief Financial Officer1.2yrsUS$1.00mno data
Susan Schneider
Chief Medical Officerless than a yearUS$832.63kno data
Nicholas Muzyczka
Co-Founder23.8yrsno datano data
Barry Byrne
Co-Founder23.8yrsno datano data
William Hauswirth
Co-Founder & Member of Ophthalmology Scientific Advisory Boardno datano datano data
Richard Samulski
Co-Founder23.8yrsno datano data
Terence Flotte
Co-Founder23.8yrsno datano data
Gerald Reynolds
Chief Accounting Officer1.4yrsno data0.013%
$ 1.6k
Abraham Scaria
Chief Scientific Officerless than a yearno datano data
Hope D'Oyley-Gay
General Counselless than a yearno datano data
David Knop
Senior Vice President of Process & Assay Developmentless than a yearUS$141.25kno data

1.4yrs

Average Tenure

57yo

Average Age

Experienced Management: AGTC's management team is not considered experienced ( 1.4 years average tenure), which suggests a new team.

Board Members

NamePositionTenureCompensationOwnership
Susan Washer
President19yrsUS$1.47m0.21%
$ 26.7k
William Hauswirth
Co-Founder & Member of Ophthalmology Scientific Advisory Boardno datano datano data
Edward Hurwitz
Independent Director10yrsUS$65.23k0.041%
$ 5.1k
Anne VanLent
Independent Director6.3yrsUS$79.23kno data
Scott Koenig
Independent Chairman of the Board20.6yrsUS$101.50k0.051%
$ 6.4k
David Birch
Member of Ophthalmology Scientific Advisory Boardno datano datano data
William Aliski
Independent Director4.2yrsUS$78.23k0.013%
$ 1.6k
Peter Campochiaro
Member of Ophthalmology Scientific Advisory Boardno datano datano data
James Rosen
Independent Director12.7yrsUS$72.34k0.0015%
$ 186.7
Paul Kaufman
Member of Ophthalmology Scientific Advisory Boardno datano datano data
Stephen Daiger
Member of Ophthalmology Scientific Advisory Boardno datano datano data
Robert Molday
Member of Ophthalmology Scientific Advisory Boardno datano datano data

11.3yrs

Average Tenure

65.5yo

Average Age

Experienced Board: AGTC's board of directors are seasoned and experienced ( 11.3 years average tenure).

Simply Wall St™
Simply Wall Street Pty Ltd
Level 7, 320 Pitt Street, Sydney
Download on the App StoreGet it on Google Play
Popular Markets
USAUUKINCAZA
About UsCareersPlansLogin
Help CenterLatest CoveragePodcastsAffiliate ProgramBusiness & Enterprise
Financial Services GuideTerms and ConditionsPrivacy PolicyLogos provided by Clearbit
Simply Wall Street Pty Ltd (ACN 600 056 611), is a Corporate Authorised Representative (Authorised Representative Number: 467183) of Sanlam Private Wealth Pty Ltd (AFSL No. 337927). Any advice contained in this website is general advice only and has been prepared without considering your objectives, financial situation or needs. You should not rely on any advice and/or information contained in this website and before making any investment decision we recommend that you consider whether it is appropriate for your situation and seek appropriate financial, taxation and legal advice. Please read our Financial Services Guide before deciding whether to obtain financial services from us.